Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a biotechnology leader developing innovative therapies for rare diseases, including hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta syndrome (APDS). This page provides investors and healthcare professionals with direct access to the company's latest press releases and official announcements.
Track PHARM's progress through updates on clinical trials, regulatory milestones, and commercialization efforts for therapies like RUCONEST® and Joenja®. Our curated news feed ensures you stay informed about earnings reports, strategic partnerships, and market expansion initiatives without extraneous information.
Discover updates categorized for quick navigation, including product development breakthroughs, financial performance disclosures, and operational strategy refinements. All content is sourced directly from Pharming's verified communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PHARM's evolving story in rare disease treatment. Check regularly for new developments that demonstrate the company's commitment to addressing unmet medical needs through biopharmaceutical innovation.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announced its participation in three key investor conferences in June 2024. CEO Sijmen de Vries will present at the Jefferies Healthcare Conference in New York on June 5. CMO Anurag Relan will join a panel at the Oppenheimer Novel Targets in Immunology Summit on June 24. Additionally, Pharming will attend the Oppenheimer 2024 Montauk Life Sciences Summit from June 26-28. These events aim to provide investors with insights into the company's progress and future plans. Live webcasts and replays will be available on Pharming's website.
Pharming Group has provided an update on the regulatory review of leniolisib for treating APDS in the EU. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has affirmed the clinical benefit and safety of leniolisib but requested further clarification on manufacturing controls before approval.
Pharming has been granted an extension to January 2026 to fulfill these requirements. Despite the delay, leniolisib has shown positive efficacy and safety in clinical trials, meeting co-primary endpoints and benefiting patients in long-term studies. The drug is already approved in the US since March 2023. Pharming maintains its 2024 revenue guidance.
Pharming Group announced the results of its 2024 Annual General Meeting (AGM) held on May 21, 2024. All proposals were approved by shareholders, including the reappointment of Ms. Barbara Yanni and Mr. Mark Pykett as Non-Executive Directors for four years. The updated Remuneration Policy for the Board was also accepted. Additionally, shareholders authorized the Board to issue shares and/or options and to repurchase shares. Detailed information and a recording of the AGM are available on Pharming's Investor Relations webpage.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will be held at NASDAQ, New York, on May 20, 2024.
Michael Levitan, VP of Investor Relations and Corporate Communications, will deliver a presentation at 09:30 EDT/15:30 CET. Investors interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their H.C. Wainwright representative.
Pharming Group has announced the early redemption of the remaining €1.9 million in 3.00% convertible bonds due 2025. Originally, €125 million in bonds were issued, but €123.1 million were repurchased by Pharming on 26 April 2024. The remaining bonds will be redeemed on 18 June 2024 at 100% of their principal amount, with accrued interest paid up to the redemption date. Bondholders have until 7 June 2024 to exercise their conversion rights at a price of €2.0028 per ordinary share. As of the latest trading session, Pharming's stock closed at €0.868.
Pharming Group N.V. reported a strong first quarter in 2024 with a 31% revenue increase to US$55.6 million driven by the U.S. launch of Joenja® and RUCONEST® growth. The company is on track to meet its 2024 revenue guidance of US$280-295 million. Pharming is actively finding more APDS patients and expanding leniolisib availability globally. Leniolisib clinical trials for pediatric and additional indications are progressing. The company refinanced convertible bonds to strengthen its financial position.
